SCHEMBL6444771

SCHEMBL6444771

Clc1cccc(Cl)c1N(Cc1ccccc1)c1[c]cccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 1/20 0.37
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
PMP22 Q01453 1/20 0.36
KMT2A Q03164 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.33
ALDH1A1 P00352 1/20 0.32
P2RX7 Q99572 2/20 0.32
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
DRD3 P35462 1/20 0.31
MGLL Q99685 1/20 0.31
TMEM97 Q5BJF2 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
HTT P42858 1/20 0.31
AOC3 Q16853 1/20 0.31
G6PC1 P35575 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7798532 0.73 ALDH1A1 (0.39) TSHRLMNAALDH1A1MGLLHTT
SCHEMBL4535438 0.72 TSHR (0.44) TSHRCYP2D6LMNAKMT2AALDH1A1
SCHEMBL1045949 0.69 TSHR (0.48) TSHRLMNAKMT2AALDH1A1MGLL
SCHEMBL5554891 0.67 TSHR (0.56) TSHRMAPK1LMNAKMT2AALDH1A1
SCHEMBL6554087 0.67 TSHR (0.39) TSHRLMNAALDH1A1MGLLSIGMAR1
SCHEMBL10439811 0.67 CYP2D6 (0.36) TSHRCYP2D6CYP2C9MAPK1LMNA
SCHEMBL6553674 0.66 G6PC1 (0.44) MAPK1MEN1KMT2AALDH1A1HTT
SCHEMBL10802924 0.65 CXCL8 (0.46) TMEM97SIGMAR1HTT
SCHEMBL6444732 0.65 NR3C1 (0.38) TSHRCYP2D6CYP2C9MAPK1LMNA
SCHEMBL6554156 0.64 ALDH1A1 (0.42) TSHRCYP2D6CYP2C9LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 US disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 EP disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 TSHR 2585/4885CYP2D6 3661/4885CYP2C9 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.